A5011834461- Cancer Immunotherapy and Biomarkers
- Renal Diseases and Glomerulopathies
- Renal cell carcinoma treatment
- Renal Transplantation Outcomes and Treatments
- CAR-T cell therapy research
- Nephrotoxicity and Medicinal Plants
- Polyomavirus and related diseases
- Electrolyte and hormonal disorders
- COVID-19 and healthcare impacts
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Drug-Induced Adverse Reactions
- Acute Kidney Injury Research
- Complement system in diseases
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Parathyroid Disorders and Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Pancreatic and Hepatic Oncology Research
- Chronic Myeloid Leukemia Treatments
- Chemotherapy-related skin toxicity
- Hematopoietic Stem Cell Transplantation
- Eosinophilic Disorders and Syndromes
- Vasculitis and related conditions
- Peptidase Inhibition and Analysis
The University of Texas MD Anderson Cancer Center
2019-2025
The University of Texas Health Science Center at Houston
2018-2020
University of Houston
2020
Brookdale University Hospital and Medical Center
2017
Harvard University
2012
Significance Statement Kidney toxicity from use of immune checkpoint inhibitors is being recognized as an increasingly frequent complication treatment. However, existing data on inhibitor–associated AKI have been limited to small, mostly single-center studies. In this multicenter study 138 patients with and 276 controls, the authors characterize clinical features identify risk factors associated its development, clinicopathologic features, determinants kidney recovery after episode. Failure...
<h3>Rationale & Objective</h3> The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, related toxicities associated with CPI can limit efficacy of these agents. literature on nephrotoxicity is limited. Here, we present cases biopsy proven acute tubulointerstitial nephritis (ATIN) and glomerulonephritis (GN) induced by CPIs discuss potential mechanisms adverse effects. <h3>Study design,...
Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. Methods We collected data on 429 ICPi-AKI and control who received ICPis contemporaneously but did not develop from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of its recovery. A multivariable Cox model estimate the effect ICPi rechallenge versus no survival following ICPi-AKI. Results occurred at a...
Acute tubular interstitial nephritis (ATIN) is the most frequently reported pathology in patients with checkpoint inhibitor (CPI) induced acute kidney injury (AKI). Glucocorticoid (GC) therapy and discontinuation of CPI are mainstay treatment to prevent permanent renal dysfunction dialysis. However, less than 50% have complete recovery relapse ATIN can occur. Infliximab effective treating other immune-related adverse events but its use for CPI-ATIN not well established. We report first...
Background: The incidence of renal immune-related adverse events (irAEs) is reported to be 3.8%, with varied definitions acute kidney injury (AKI). This study reports a 10-year experience at MD Anderson Cancer Center patients diagnosed melanoma and treated immune checkpoint inhibitors (ICIs) evaluated the AKI, associated factors, its association overall survival.Methods: A retrospective chart review (2010–2019) all ipilimumab, nivolumab, pembrolizumab, or atezolizumab was performed. All...
The percentage of patients with cancer eligible for checkpoint inhibitor (CPI) therapy has increased rapidly over the past few years and approaches 45%. As a result, more cases CPI-related nephrotoxicity, including rare subset vasculitis, are being reported. To elucidate clinical presentation CPI-associated renal vasculitis its possible mechanisms, treatment options prognosis, we describe from comprehensive center reviewed literature similar cases. We retrospectively charts all 2014 to 2020...
The same mechanisms that mediate antitumor immunity from checkpoint inhibitors (CPIs) can also lead to unintended targeting of normal tissues, characterized as immune-related adverse events (irAEs). Those with pre-existing autoimmune disease are believed be particularly vulnerable for exacerbating underlying autoimmunity or inducing severe irAEs. We report the first case CPI-associated reactivation primary membranous nephropathy (MN) in a patient pleural mesothelioma responding...
Hyponatraemia in cancer patients admitted to the hospital is associated with longer stays, higher costs and increased mortality. We examined impact of hyponatraemia correction on survival hospitalized advanced cancer. reviewed records solid tumours who were between January 2018 December 2022 serum sodium ≤125 mEq/l at admission. Cox regression analysis associations demographic clinical characteristics, including levels admission discharge, overall survival. Among 1100 patients, median 122...
Dysregulation of phosphorus homeostasis resulting in hypophosphatemia is common cancer patients and can result serious complications impact outcomes. Several factors, including critical illness, nutritional status, type therapy, influence the development hypophosphatemia. Hypophosphatemia develop as a phosphaturic mesenchymal tumors or paraneoplastic phenomenon. The clinical presentation for varies depending on duration severity affects several organ systems. Among other effects, impair...
Background: Immune-related adverse events (irAEs) challenge the use of immune checkpoint inhibitors (ICIs). We performed a retrospective study to evaluate response infliximab for immune-related event management, and infliximab’s effect on progression-free survival (PFS) overall (OS) with focus melanoma genitourinary cancers. Methods: retrospectively reviewed records all cancer patients exposed after inhibitor (ICI) treatment from 2004 2021 at MD Anderson Cancer Center. Survival was assessed...
Purpose: To investigate the ability of human lymphocytes labeled with DNA-incorporated 125I to exert an inhibitory (antiproliferative) bystander effect on co-cultured colon adenocarcinoma LS174T cells in vitro.Materials and methods: Human peripheral blood were stimulated synthesize DNA presence phytohemagglutinin (PHA) 5-[125I]iodo-2′-deoxyuridine. 125I-labeled various ratios for 5 days proliferation was assessed. Further, supernatant media from these co-cultures were: (i) Transferred their...
Background: Immune-related adverse events are a management challenge in patients receiving immune checkpoint inhibitors (ICIs). The most common renal immune-related event, acute interstitial nephritis (AIN), is associated with patient morbidity and mortality. AIN, characterized by infiltration of tissue cells, may be analogous to kidney transplant rejection. We evaluated clinical variables pathologic findings identify predictors response overall survival (OS) ICI-induced AIN. Design,...
With the advent of era immunotherapy, there has been marked increased survival in several cancers such as advanced melanoma, renal cell carcinoma, non-small lung cancer, urothelial and head neck cancers. Harnessing immune system against tumor by releasing breaks off regulators system, cytotoxic T-lymphocyte–associated antigen 4, programmed death protein 1, its ligand, resulted also unregulated organ-specific toxicity. In this review, we will discuss toxicities associated with a checkpoint...
Drug-induced lupus glomerular diseases have historically been associated with hydralazine, but new drugs that modify the growth, metabolism, and immunity of cells are increasingly found to cause disease. This includes anti–tumor necrotic factor other antibody agents used in cancer treatment. Multitarget tyrosine kinases such as regorafenib metastatic malignancies good outcomes. Currently, they not known kidney complications except for proteinuria, hypertension, electrolyte disturbances...
The long-term impact of Autologous hematopietic stem cell transplantation (ASCT) on renal function, and the function progression-free survival (PFS) overall (OS) in patients with multiple myeloma are not known. We retrospectively reviewed records 885 at our institution. used linear mixed effect models to study change estimated glomerular filtration rate (eGFR) a joint model approach assess associations between eGFR, PFS OS. Sensitivity analyses were conducted days 0, 100, 180, 365 post-SCT....
Cancer patients are most vulnerable to the significant illness and mortality from COVID-19 infection. There is limited data regarding outcomes for with infection varying cancer types, stages, chronic kidney disease (CKD). The primary objective of this study was evaluate association between baseline function COVID19 related outcomes, including mortality, ventilatory support, ICU stay, acute injury (AKI) requiring renal replacement therapy (RRT), prolonged hospitalization in patients.